Two Rizatriptan Prescribing Portions for Treatment of Migraine
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9
rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit
(FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of
migraine per month.